A detailed history of Susquehanna International Group, LLP transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 80,845 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,845
Previous 253,416 68.1%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
N/A
-172,571 Reduced 68.1%
80,845 $0
Q4 2023

Feb 14, 2024

BUY
N/A
77,873 Added 44.36%
253,416 $0
Q3 2023

Nov 14, 2023

BUY
N/A
24,183 Added 15.98%
175,543 $0
Q2 2023

Aug 11, 2023

SELL
N/A
-161,594 Reduced 51.64%
151,360 $0
Q1 2023

May 16, 2023

BUY
N/A
267,008 Added 581.13%
312,954 $0
Q4 2022

Feb 14, 2023

BUY
$0.0 - $6.07 $0 - $278,892
45,946 New
45,946 $0
Q2 2022

Aug 15, 2022

BUY
$2.9 - $4.44 $439,587 - $673,024
151,582 New
151,582 $643,000

Others Institutions Holding SBTX

About Silverback Therapeutics, Inc.


  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.